Novartis received European Commission approval for Itvisma, its gene therapy for patients with 5q spinal muscular atrophy across children, teenagers, and adults. This regulatory milestone expands the treatment’s addressable market in the EU and is a positive catalyst for the program’s commercialization outlook.
Novartis received European Commission approval for Itvisma, its gene therapy for patients with 5q spinal muscular atrophy across children, teenagers, and adults. This regulatory milestone expands the treatment’s addressable market in the EU and is a positive catalyst for the program’s commercialization outlook.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
moderately positive
Sentiment Score
0.45
Ticker Sentiment
